Category
Gynecological tumors / Breast cancer, Pediatric oncology/hematology
Subcategory
Germ cord stroma tumor, Solid tumors
Trial Type
other systemic therapies
Description for experts
A randomized comparison will be conducted to determine whether the efficacy of carboplatin is non-inferior to that of cisplatin in the treatment of intermediate, high or very high risk malignant germ cell tumors in terms of event-free survival (EFS).
Description for laymen
A randomized comparison will be conducted to determine whether the efficacy of carboplatin is non-inferior to that of cisplatin in the treatment of intermediate, high or very high risk malignant germ cell tumors in terms of event-free survival (EFS).
JSON Data
{
"short_title": "Makei V",
"data_mode": "900",
"data_mode_number": "000002179",
"official_title": "Multizentrische prospektive Studie zu einem randomisierten Vergleich von Carboplatin mit Cisplatin bei extrakraniellen malignen Keimzelltumoren",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "kurativ",
"therapieintervention_value": null,
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": null,
"general_contact_email": "studiensekretariat.gyn@ukdd.de",
"general_contact_phone": "+49 351-4584202",
"hauptpruefer_dd_name": "Dr. med. Judith Lohse",
"description_laie_de": "Anhand eines randomisierten Vergleichs soll beurteilt werden, ob die Wirksamkeit von Carboplatin der von Cisplatin bei der Behandlung von malignen Keimzelltumoren mit mittlerem, hohem oder sehr hohem Risiko in Bezug auf das ereignisfreie \u00dcberleben (EFS) nicht unterlegen ist.",
"description_laie_en": "A randomized comparison will be conducted to determine whether the efficacy of carboplatin is non-inferior to that of cisplatin in the treatment of intermediate, high or very high risk malignant germ cell tumors in terms of event-free survival (EFS).",
"description_expert_de": "Anhand eines randomisierten Vergleichs soll beurteilt werden, ob die Wirksamkeit von Carboplatin der von Cisplatin bei der Behandlung von malignen Keimzelltumoren mit mittlerem, hohem oder sehr hohem Risiko in Bezug auf das ereignisfreie \u00dcberleben (EFS) nicht unterlegen ist.",
"description_expert_en": "A randomized comparison will be conducted to determine whether the efficacy of carboplatin is non-inferior to that of cisplatin in the treatment of intermediate, high or very high risk malignant germ cell tumors in terms of event-free survival (EFS).",
"rechtsgrundlage_value": "BO",
"phase_amg_value": null,
"main_cat_id": 14,
"sub_cat_id": 63
}
